Professional background

Dr Flynn is a Medical Oncology Consultant. He completed his PhD in antibody drug conjugate translational development at University College London and his specialist training at the Royal Marsden Hospital. 

Previously, Dr Flynn worked as a Phase I Clinical Research Fellow within UCLH's Clinical Research Facility for several years, during which time he was a sub-investigator on a number of first-in-man and later Phase development clinical trials. He is a now Principal Investigator on gynae-specific and sub-investigator on tumour-agnostic targeted therapy, immunotherapy and combination trials whilst continuing to expand his trial portfolio.

Research interests

Gynae-oncology, Early Phase trials


Selected publications:

1. Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer. Flynn MJ, Ledermann JA. Cancer Drug Resistance. 2022,5:424-35
2.ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies. Flynn MJ, Zammarchi F, Tyrer PC, Akarca AU, Janghra N, Britten CE, Havenith CE, Levy JN, Tiberghien A, Masterson LA, Barry C, D'Hooge F, Marafioti T, Parren PW, Williams DG, Howard PW, van Berkel PH, Hartley JA. Mol Cancer Ther. 2016 Nov;15(11):2709-2721